Eli Lilly immunology revenue rises 9% in H1 2026 to $2.6B on DICE and Morphic M&A
Question
Eli Lilly immunology revenue rises 9% in H1 2026 to $2.6B on DICE and Morphic M&A
Direct answer
Acquired immunology pipelines from DICE, Morphic, and Merida drive $2.6 billion in H1 revenue, reducing Eli Lilly's concentration risk on GLP-1 drug franchises. — bullish pressure on LLY via revenue diversification via immunology M&A integration.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-12
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Eli Lilly immunology revenue rises 9% in H1 2026 to $2.6B on DICE and Morphic M&A”, revision 1, evidence through 2026-09-12. https://marketontology.com/catalysts/2026-09-12/eli-lilly-immunology-revenue-rises-9-in-h1-2026-to-2-6b-on-dice-and-morphic-m-a-67a43e
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| LLY | ▲Bull | 1–3 months | revenue diversification via immunology M&A integration | 71 |
Eli Lilly immunology revenue rises 9% in H1 2026 to $2.6B on DICE and Morphic M&A
Acquired immunology pipelines from DICE, Morphic, and Merida drive $2.6 billion in H1 revenue, reducing Eli Lilly's concentration risk on GLP-1 drug franchises. — bullish pressure on LLY via revenue diversification via immunology M&A integration.
Immunology revenue generated $2.6B in H1 2026 (+9% YoY) via DICE, Morphic, and Merida acquisitions.
- SourceImmunology revenue generated $2.6B in H1 2026 (+9% YoY) via DICE, Morphic, and Merida acquisitions.
- TransmissionAcquired immunology pipelines from DICE, Morphic, and Merida drive $2.6 billion in H1 revenue, reducing Eli Lilly's concentration risk on GLP-1 drug franchises.
- SummaryEli Lilly generated $2.6 billion in H1 2026 immunology revenue, up 9% year-over-year. The segment represents 6.1% of total corporate revenues, supported by Taltz, Ebglyss, and Omvoh. Growth reflects integration of strategic M&A deals including DICE, Morphic, and Merida.
- LLYDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- LLY closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- LLY price vs. pre-event level
- LLY volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s · polygon_news · 2026-09-11
Related catalysts
- 2026-10-19Viking Therapeutics Raises $575 Million to Fund Phase 3 Obesity TrialsLLY VKTX
- 2026-10-19Viking Therapeutics Raises $575 Million to Fund Phase 3 Obesity TrialsLLY VKTX
- 2026-10-19Viking raises $575 million to fund obesity pipeline trialsLLY VKTX
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY SPY
- 2026-10-19Viking raises $575 million to fund obesity trials through 2028LLY NVO VKTX
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY
- 2026-10-19Viking Therapeutics Raises $575M in Equity and Convertibles for Phase 3 TrialsLLY VKTX
- 2026-10-19Viking financing keeps obesity trial runway open through 2028LLY VKTX
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.